Click here to download company's press release

Document Sample
Click here to download company's press release Powered By Docstoc

      AMO Launches First-of-its-Kind Regional Training Facility in Singapore
   This S$1.5M Centre of Excellence will showcase the latest surgical and technology
innovations and will provide a training facility for more than 100 eye care specialists from
                                   Asia Pacific annually

Singapore, 15 October 2008 –The Advanced Medical Optics group of companies (AMO)
today launched its Asia Pacific Technical, Training and Education Centre in Singapore.
This facility caters to eye care specialists in Asia Pacific and affirms AMO’s commitment
to Singapore, bringing its total investment in the city-state to more than S$40 million.

This Centre of Excellence, one of the largest of its kind in Asia Pacific, is set to train
more than 100 eye care specialists and engineers from the region annually on the use of
AMO products. The centre will provide a location for training in the latest surgical
procedures for cataracts as well as refractive laser eye surgery. This includes iLasik,
which utilizes NASA-approved technologies, as well as the only LASIK mono-vision
procedure used to correct presbyopia, a condition where the eye’s ability to focus on
near objects progressively diminishes with age.

Cataracts continue to be one of the leading causes of preventable blindness and this
Centre will provide facilities for training on the newest technology to restore vision to
cataract patients. Approximately 32 million LASIK procedures have been performed to
date, with well documented results for high visual outcomes. In a clinical evaluation
employing AMO technology, ninety-eight percent of nearsighted patients participating in
the Advanced CustomVue™ FDA clinical trials could see 20/20 or better one year after

“As part of our commitment to Eye Care in Singapore and Asia Pacific, we have
established this training facility to allow professionals to develop the skills to correct
patients’ vision using some of the most innovative refractive technology. This is intended
to positively impact patients as they stand to directly benefit from cutting-edge surgery

                                                                                       1 of 3
techniques performed by skilled individuals” said Angelo Rago, Senior Vice President,
AMO Global Customer Services.

The centre will also offer training on AMO products to engineers who will be able to
support clinicians in installing and operating this equipment on an ongoing basis. This
will help to ensure that the equipment is used appropriately and is well maintained.

Beyond offering new technical skills, the centre will allow clinicians from around the
region to share best practices and could in the future be used for clinical testing, further
enhancing Singapore’s position as a medical hub for patient care, research and training.

“We are pleased that AMO, a world leader in ophthalmic care, is expanding its
international headquarters in Singapore with the opening of this regional training facility,”
said Aw Kah Peng, Assistant Managing Director, Singapore Economic Development
Board. “AMO will enhance Singapore’s overall position in Vision Care, as we develop a
full range of capabilities in clinical training, research and development, manufacturing
and global distribution of ophthalmic products.”

This announcement is the latest in a series of investments by the company in Singapore.
AMO Singapore Pte. Ltd. has been awarded International Headquarters status by the
Singapore Economic Development Board. Since 2005, AMO has made Singapore its
regional hub by bringing into Singapore its regional leadership team and centralising
back office functions for Asia Pacific, including its regional staff members.

About Advanced Medical Optics (AMO)
AMO is focused on providing the full range of advanced refractive technologies and
support to help eye care professionals deliver optimal vision and lifestyle experiences to
patients of all ages. Products in the cataract line include monofocal intraocular lenses
(IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular
surgery. AMO owns or has the rights to such product brands as Tecnis®, Clariflex® and
Sensar® IOLs; Sovereign®, Sovereign® Compact and WhiteStar Signature™
phacoemulsification systems with WhiteStar® technology; Healon® viscoelastics and the
Baerveldt® glaucoma shunt. Products in the refractive line include wavefront diagnostic
devices, femtosecond lasers and associated patient interface devices; excimer laser
vision correction systems and treatment cards, and refractive implants. AMO brands in
the refractive business include iDesign™, iFS™, Star S4 IR®, WaveScan Wavefront®,
Advanced CustomVue™, IntraLase®, IntraLasik® and ReZoom®, Tecnis® Multifocal

                                                                                        2 of 3
and Verisyse® IOLs. Products in the eye care line include disinfecting solutions,
enzymatic cleaners, lens rewetting drops and artificial tears. Among the eye care
product brands the company possesses are COMPLETE®, COMPLETE® Blink-N-
Clean®, Consept®F, Consept® 1 Step, Oxysept® 1 Step, UltraCare®, Ultrazyme®,
Total Care™ and blink® branded products. AMO is based in Santa Ana, California, and
employs approximately 4,000 worldwide. The company has operations in 30 countries
and markets products in approximately 60 countries. For more information, visit the
company's Website at

Forward-Looking Statements
This press release contains forward-looking statements about AMO, including the
statement by Mr. Rago and statements relating to the training planned at the facility on
the latest surgical and technology innovations in the cataract and refractive vision
correction fields. All forward-looking statements in this press release represent AMO's
judgment only as of the date of this press release. Actual results may differ from current
expectations based on a number of factors, including, but not limited to, unexpected
delays or costs associated with the development of training programs, physician and
engineer participation in the programs, and continued acceptance and performance of
our products. Therefore, the reader is cautioned not to rely on these forward-looking
statements. AMO disclaims any intent or obligation to update these forward-looking
statements. Additional information concerning these and other risk factors may be found
in previous press releases issued by AMO and AMO's public periodic filings with the U.S.
Securities and Exchange Commission, including the discussion under the heading "Risk
Factors" in AMO's 2007 Form 10-K filed in March 2008. Copies of press releases and
additional information about AMO are available at

For further information, comment and photograph, please contact:

Yanni Yoong: // 6347 2304
Nicole Lim: // 6347 2341
Delicia Tan: // 6347 2325

                                                                                    3 of 3